Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

Ocular Therapeutix announced the company’s conference participation in the upcoming annual OIS Retina Innovation Summit, the American Society of Retina Specialists (ASRS), and Women in Ophthalmology ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.

Advertorial: Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy? The triad of inflammation, neuropathy, and vasculopathy plays a key role ...

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.